Physician profile
Amy Darwin
NPI 1407827660
$762.98
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2023: $21.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.74 | 2019 | |
| Novo Nordisk INC | $140.34 | 2019 | |
| Sunovion Pharmaceuticals INC. | $49.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.14 | 2019 | |
| Sanofi Pasteur INC. | $39.04 | 2019 | |
| Glaxosmithkline, LLC. | $33.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.67 | 2019 | |
| Pfizer INC. | $30.99 | 2019 | |
| Amarin Pharma, INC. | $29.62 | 2019 | |
| Lilly USA, LLC | $27.58 | 2019 | |
| Amgen INC. | $25.29 | 2019 | |
| Abbvie INC. | $21.38 | 2023 | Creon, Linzess |
| Avanir Pharmaceuticals, INC. | $14.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.52 | 2019 | |
| Biodelivery Sciences International, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Darwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.